This page aims to provide guidance and advice for recruiting patients to BADBIR using postal consent and conducting follow-ups remotely. It is based on the most common questions received from centres on best practice. The following areas are covered, but please contact the BADBIR office if you have any queries:
Postal consent was introduced to BADBIR in Amendment 5 on 05/05/2011.
Eligibility criteria remains the same for patients recruited using postal consent. Please refer to the eligibility page for full information, but in summary:
- The patient has to sign the consent form within 6 months of starting their registration drug
- A DLQI is required for all registrations, dated as close to the start date of their registration drug as possible
- A PASI is required for all registrations, dated as close to the start date of their registration drug as possible
When you have identified a potential recruit for BADBIR, you can send them the patient invitation letter and the patient information sheet for them to look at, along with the consent form and baseline questionnaires to complete and return if they decide they would like to join.
When recruiting patients through postal consent, use the same consent materials as used in clinic. Localised versions can be found in your electronic site file.
When you are ready to send the documents to the patient, you can:
- Post the documents to the patient for them to return by post
- Post the documents to the patient for them to complete before taking a photo/scan and emailing it back to the dermatology department
- Email the documents to the patient for them to print out and complete, before taking a photo/scan to email back to the dermatology department
Email should only be used for sending or receiving consent forms if you have local approval to do so. If you have local approval, we have no objection. If email is used to exchange documentation, this must be in line with your local policies regarding information security.
For patients recruited through postal consent, it’s acceptable for the date of signature for patient and person-taking-consent to differ.
Here is the full list of items we require at baseline for all patients, including those recruited using postal consent:
Standard clinical information, including:
- Psoriasis history
- Current drugs
- Past psoriasis treatments
- Fitzpatrick skin type
- History of lesions
- Height measurement
- Patient Baseline Questionnaire
You may wish to consider sending the Patient Baseline Questionnaire and DLQI to the patient with the consent form, so that the patient can complete and return them at the same time.
As the presence of the PASI and DLQI are necessary for registration, we recommend you have these ready as soon as you add the patient to the database. If there is a slight delay in getting the other information, such as a height measurement, this is acceptable but a query will be raised on the database to remind you that we need this information at some stage.
Unfortunately we can’t provide additional funding for postage or pre-paid envelopes. If you require funding for postage costs, we suggest contacting your R&D department to ask if you can be allocated money from BADBIR payments for this purpose.
Completing Follow-up Remotely
When you are gathering information for a follow-up remotely, your priorities should be:
- Drug changes
- Adverse events
One of the changes included in Amendment 12 is the ability for us to collect self-assessed PASI from patients. The data entry system to collect SAPASI directly from participants is currently in development and more information will follow soon. If you are already collecting SAPASI routinely at your centre, we can accept them.
If you can’t get a PASI from clinic, at present we’re still paying for follow-ups which are conducted remotely. Make sure that you indicate that the follow-up was conducted remotely when you enter it onto the database.
We are working on an app and web portal for patients to complete the questionnaires at home. We will provide more information when possible.
To collect the patient completed questionnaires in the interim, centres have used the following methods. Please note these have been done by local arrangement at centres and are not mandated in the BADBIR protocol:
- Post the questionnaires to the patient for them to complete and return to you through post
- Post the questionnaires to the patient for them to complete before taking a photo/scan and emailing it back to the dermatology department
- Email the questionnaires to the patient for them to print out and complete, before taking a photo/scan to email back to the dermatology department
The following methods are not recommended:
- Completing the questionnaires with the patient over the phone
- The patient typing out their answers to the questionnaires in an email to you
If you can’t get the patient completed questionnaires, please mark as ‘Not completed’ when you enter the follow-up onto the database.
We have heard from some BADBIR centres who have telephoned participants for additional information outside of their normal appointment. For example, when the person conducting the original appointment didn’t get everything required for BADBIR (e.g. additional details on adverse events). If choosing to do this it is entirely your decision. As long as you have local approval to make this additional contact, then we don’t have any objections.
As the patient is not being seen in person it is important to ask them whether they have had any adverse events since their last BADBIR follow up.
- Coughs, colds, chest infections
- Any new diagnoses or exacerbations of comorbidities
- Any new injuries, fractures or visits to A&E
- Any overnight hospitalisations, IV antivirals, pregnancies or cancers (including skin cancers)
- Any new COVID-19 diagnoses or suspected cases (please specify whether the patient tested positive or not)
It is important to obtain as much detail as possible about adverse events, including the dates of events (estimated where necessary).